[Resection and reconstruction of the retrohepatic vena cava in combination with liver resections].
Liver resection combined with the resection and reconstruction of the vena cava represents the only potential curative therapy for malignant hepatic tumors with invasion of the vena cava. We performed a liver resection with segmental replacement of the retrohepatic vena cava by synthetic grafts in 29 patients. In three cases, the additional presence of central involvement of all three hepatic veins required ex situ tumor resection. Four patients underwent a simultaneous exstirpation of the primary tumor (kidney or suprarenals). The remaining hepatic veins were reimplanted into the graft in three cases, and in two cases the renal veins were reimplanted. There was no perioperative mortality. A distal arteriovenous fistula was not applied. Five patients revealed postoperative transient liver insufficiency, requiring temporary dialysis in three cases. Two of these patients developed a transient multiorgan failure with the need of mechanical ventilation. 18 patients died during the course of follow-up, 17 of these cases due to recurrent metastases of the primary disease. Infection or thrombosis of the prosthetic vascular graft have not been observed. Beside tumor exstirpation, extended liver resection and concomitant vena cava replacement may prevent embolism as well as the obstruction of the vena cava with lower extremity swelling and the possibility of developing a Budd Chiari syndrome. We were able to achieve a long-term survival for surgically treated patients even in cases with advanced tumor stages.
Settmacher
U
U
Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Campus Virchow Klinikum, Charité, Humboldt Universität zu Berlin. utz.settmacher@charite.de
Thelen
A
A
Jonas
S
S
Husmann
I
I
Heise
M
M
Neuhaus
P
P
D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000601:surgery*; D001807:Blood Vessel Prosthesis; D006528:Carcinoma, Hepatocellular / Q000601:surgery*; D016461:Chemoembolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D006500:Hepatic Duct, Common; D006801:Humans; D007431:Intraoperative Complications; D018285:Klatskin Tumor / Q000601:surgery*; D008099:Liver / Q000601:surgery*; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D011138:Polytetrafluoroethylene; D011183:Postoperative Complications; D016019:Survival Analysis; D013997:Time Factors; D019043:Vascular Neoplasms / Q000401:mortality / Q000601:surgery*; D014682:Vena Cava, Inferior / Q000601:surgery*
D011138:Polytetrafluoroethylene